Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 277 publications
Efficacy of high-frequency low-dose rituximab and acalabrutinib in chronic lymphocytic leukemia.
Journal: HemaSphere
Published: February 24, 2026
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma.
Journal: Future oncology (London, England)
Published: December 10, 2025
Reply to: Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 21, 2025
Brentuximab vedotin and dose attenuated chemoimmunotherapy for patients 75 years and older with diffuse large B-cell lymphoma with analysis of outcomes by frailty.
Journal: Journal of geriatric oncology
Published: October 31, 2025
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.
Journal: Journal of geriatric oncology
Published: September 26, 2025
Real World Data Identifies Care Needs in Adolescent and Young Adult Patients with Lymphoma: A Matched Cohort Study.
Journal: Journal of adolescent and young adult oncology
Published: September 03, 2025
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 29, 2025
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 27, 2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 06, 2025
Feasibility of Bruton's Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient Perspective.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 11, 2025
Treatment of Relapsed/Refractory CLL Patients With PI3Kδ Inhibitor and Anti-CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance.
Journal: American journal of hematology
Published: September 24, 2024
Last Updated: 09/26/2026